The observed pro-apoptotic and pro-differentiating activity of S63845 enhanced by the combination with BCL-2/BAX or MAPK inhibitors provides the rationale for further studies regarding the use of this strategy in AML therapy. Here, BCL2 is linked to acute myeloid leukemia.